Skip to main content

Table 1 Patient, tumor, and treatment characteristics

From: Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer

 

n (%)

Age at diagnosis (years), Median; range

63.8; 44.1–82.7

Female gender

84 (79.2)

Active smoking

32 (30.2)

Charlson comorbidity index ≥ 1

44 (41.5)

Sarcopenia

41 (38.7)

Immunosuppressive disordersa

12 (11.3)

HIV

1 (0.9)

Pretreatment hemoglobin (g/L), Median; range

129; 77–163

Pretreatment leukocyte count (109/L), Median; range

7.6; 3.8–33.7

T stageb

 

 1

3 (2.8)

 2

46 (43.4)

 3

27 (25.5)

 4

30 (28.3)

Primary tumor size (cm), Median; range

5.0; 1.0–15.0

Lymph node metastasisb

67 (63.2)

Radiation technique

 

 IMRT

9 (8.5)

 Tomotherapy

20 (18.9)

 VMAT

77 (72.6)

Radiation dose (Gy)

 

 Primary tumor, Mean; SD

59.5; 1.2

 Lymph node metastasis, Mean; SD

57.9; 4.4

 Elective, Mean; SD

45.1; 4.0

Radiation treatment time (days), Mean; SD

43.1; 4.6

Included in elective CTVc

 

 Inguinal

104 (98.1)

 Internal iliac

106 (100.0)

 External iliac

104 (98.1)

 Presacral

106 (100.0)

 Mesorectal

106 (100.0)

 Ischiorectal fossa

101 (95.3)

Low cranial borderd of elective CTV

8 (7.5)

Chemotherapy: all patients scheduled for FUMI × 2

 

 Omission of second cycle

14 (13.2)

 Dose reduction of second cycle

15 (14.2)

 Omission or dose reduction of second cycle

29 (27.4)

 Second cycle platinum-based (cardiac toxicity)

4 (3.8)

White blood cell toxicity (CTCAE version 5.0)

 

 G0

15 (14.2)

 G1

7 (6.6)

 G2

30 (28.3)

 G3

36 (34.0)

 G4

18 (17.0)

Febrile neutropenia

22 (20.8)

  1. cc cubic centimeter, CTV clinical target volume, FUMI 5-fluorouracil + Mitomycin C, G grade, Gy gray, IMRT intensity modulated radiation therapy, SD standard deviation, VMAT volumetric modulated arc therapy
  2. aConnective tissue disorder (n = 6), inflammatory bowel disease (n = 4), chronic leukemia (n = 1), heart transplant (n = 1)
  3. bTNM8
  4. c > 80% of region covered in elective CTV to count as ‘included’
  5. d ≥ 3 cm below sacral promontory (8 patients: median 36 mm; range 30–42 mm)